VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
Titel:
VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
Auteur:
Vergote, I.B. Fidalgo, A. Pérez Hamilton, E. Valabrega, G. Van Gorp, T. Sehouli, J. Cibula, D. Levy, T. Welch, S. Richardson, D.L. Alía, E.M. Guerra Scambia, G. Henry, S. Wimberger, P. Miller, D. Martínez, J. Monk, B.J. Shacham, S. Mirza, M.R. Makker, V.